{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:00:09Z","timestamp":1791216009827,"version":"4.1.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Nephropathy is one of the main features of Fabry disease (FD) that leads, in untreated patients with classical mutations, to end-stage renal disease (ESRD) from the third to the fifth decade of life. The availability of a specific treatment modified the natural history of FD; in particular, it was widely reported that enzyme replacement therapy (ERT) is able to slow the progression of the disease. Regarding Fabry nephropathy, several reports have documented an elevated estimated glomerular filtration rate (eGFR) slope in untreated patients as expression of a rapid disease progression towards ESRD. Otherwise, the prompt start of treatment may be beneficial in stabilizing renal function or slowing its decline. Therefore, based on data in the literature about the effects of ERT on eGFR decline and on the evidence supporting the role of eGFR slope as a surrogate endpoint for chronic kidney disease progression, we suggest, in this \u2018Expert Opinion\u2019, that a treatment should be defined effective when eGFR decline is &amp;lt;1\u00a0ml\/min\/1.73\u00a0m2\/year and not effective when eGFR loss remains \u22653\u00a0ml\/min\/1.73\u00a0m2\/year (\u22652.5\u00a0ml\/min\/1.73\u00a0m2\/year in females). Moreover, practical clinical recommendations and guidance for Fabry patients suggests that a change in treatment may be appropriate if individualized therapeutic goals are not achieved. Since a dose-dependent efficacy has been demonstrated for ERT, we suggest considering a switch to a higher dose of ERT in symptomatic adult Fabry patients (ages 18\u201360\u00a0years) with an eGFR of 45\u201390\u00a0ml\/min\/1.73\u00a0m2 and treated with a stable dose of ERT for at least 1\u00a0year, in which a linear negative slope of eGFR of 3\u00a0ml\/min\/1.73\u00a0m2\/year for males (2.5\u00a0ml\/min\/1.73\u00a0m2\/year for females) was observed.<\/jats:p>","DOI":"10.1093\/ndt\/gfad164","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T21:05:18Z","timestamp":1689282318000},"page":"18-25","source":"Crossref","is-referenced-by-count":11,"title":["Interpretation of GFR slope in untreated and treated adult Fabry patients"],"prefix":"10.1093","volume":"39","author":[{"given":"Antonio","family":"Pisani","sequence":"first","affiliation":[{"name":"Chair of Nephrology, Department of Public Health, Federico II University of Naples , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pieruzzi","sequence":"additional","affiliation":[{"name":"Clinical Nephrology, Fondazione IRCCS San Gerardo dei Tintori , Monza , Italy"},{"name":"School of Medicine and Surgery, University of Milano-Bicocca , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero Lino","family":"Cirami","sequence":"additional","affiliation":[{"name":"Nephrology Dialysis Transplant Unit, Careggi Hospital , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[{"name":"Chair of Nephrology, Department of Public Health, Federico II University of Naples , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Transplantation, IRCCS S. Orsola University Hospital, University of Bologna , Bologna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"2023122005152959100_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2023122005152959100_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0002-9378(90)90410-9","article-title":"Demonstration of Fabry's disease deposits in placenta","volume":"162","author":"Popli","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"2023122005152959100_bib3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr Res"},{"key":"2023122005152959100_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"2023122005152959100_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cge.12386","article-title":"The kidney in Fabry disease","volume":"86","author":"Pisani","year":"2014","journal-title":"Clin Genet"},{"key":"2023122005152959100_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2023122005152959100_bib7","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2023122005152959100_bib8","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2023122005152959100_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol Genet Metab"},{"key":"2023122005152959100_bib10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"2023122005152959100_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study group: safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"2023122005152959100_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"2023122005152959100_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"2023122005152959100_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/ijms22010206","article-title":"Fabry disease therapy: state-of-the-art and current challenges","volume":"22","author":"Azevedo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023122005152959100_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2013121322","article-title":"Fabry disease: dose matters","volume":"25","author":"Warnock","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2023122005152959100_bib16","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","article-title":"Dose dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2023122005152959100_bib17","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2023122005152959100_bib18","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages","volume":"33","author":"Kr\u00e4mer","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2023122005152959100_bib19"},{"key":"2023122005152959100_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymgme.2022.08.003","article-title":"Algasidase-\u03b2 should be proposed as first line therapy in classic male Fabry patients with undetectable \u03b1-galactosidase A activity","volume":"137","author":"Nowak","year":"2022","journal-title":"Mol Genet Metab"},{"issue":"Suppl 1","key":"2023122005152959100_bib21","first-page":"S111","article-title":"Pharmacological chaperone therapy by active- site- specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2023122005152959100_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"2023122005152959100_bib23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ajmg.a.61105","article-title":"Safety of switching to migalastat from enzyme replacement therapy in Fabry disease: experience from the phase 3 ATTRACT study","volume":"179","author":"Hughes","year":"2019","journal-title":"Am J Med Genet"},{"key":"2023122005152959100_bib24","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating Fabry disease: real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"2023122005152959100_bib25","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2014measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"2023122005152959100_bib26","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023122005152959100_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","article-title":"Longitudinal studies on the rate of decline in renal function with age","volume":"33","author":"Lindeman","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"2023122005152959100_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2003.09.026","article-title":"Measured and estimated GFR in healthy potential kidney donors","volume":"43","author":"Rule","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2023122005152959100_bib29","doi-asserted-by":"crossref","first-page":"e0173358","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"key":"2023122005152959100_bib30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10157-021-02058-z","article-title":"Pathology and pathogenic pathways in Fabry nephropathy","volume":"25","author":"Feriozzi","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2023122005152959100_bib31","doi-asserted-by":"crossref","first-page":"107558","DOI":"10.18632\/oncotarget.22505","article-title":"Genetic variants associated with gastrointestinal symptoms in Fabry disease","volume":"8","author":"Di Martino","year":"2017","journal-title":"Oncotarget"},{"key":"2023122005152959100_bib32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.33594\/000000077","article-title":"Enzyme replacement therapy clears Gb3 deposits from a podocyte cell culture model of Fabry disease but fails to restore altered cellular signaling","volume":"52","author":"Braun","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"2023122005152959100_bib33","doi-asserted-by":"crossref","first-page":"11339","DOI":"10.3390\/ijms222111339","article-title":"\u03b1-Galactosidase A deficiency in Fabry disease leads to extensive dysregulated cellular signaling pathways in human podocytes","volume":"22","author":"Jehn","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023122005152959100_bib34","first-page":"823","article-title":"Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease","volume":"2","author":"Fervenza","year":"2008","journal-title":"Biol Targets Ther"},{"key":"2023122005152959100_bib35","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.2147\/DDDT.S207856","article-title":"Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey (FOS) analysis","volume":"13","author":"Ramaswami","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"2023122005152959100_bib36","first-page":"S29","article-title":"Clinical benefits of early treatment with Fabrazyme in Fabry disease","volume":"29","author":"Waldek","year":"2007","journal-title":"Clin Ther"},{"key":"2023122005152959100_bib37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ehf2.12647","article-title":"Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis","volume":"7","author":"Wanner","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2023122005152959100_bib38","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","article-title":"Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis","volume":"4","author":"Ortiz","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023122005152959100_bib39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023122005152959100_bib40","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/DDDT.S249433","article-title":"Analysis of renal and cardiac outcomes in male participants in the Fabry Outcome Survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age","volume":"14","author":"Parini","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"2023122005152959100_bib41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/cge.14266","article-title":"New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: switch studies data following agalsidase beta shortage","volume":"103","author":"Riccio","year":"2023","journal-title":"Clin Genet"},{"key":"2023122005152959100_bib42","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"M\u00fcntze","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2023122005152959100_bib43","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023122005152959100_bib44","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate end-point for kidney failure","volume":"29","author":"Levey","year":"2023","journal-title":"Nat Med"},{"key":"2023122005152959100_bib45","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2023122005152959100_bib46","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2023122005152959100_bib47","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate endpoint for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2023122005152959100_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.arr.2014.02.003","article-title":"The aging kidney revisited: a systematic review","volume":"14","author":"Bolignano","year":"2014","journal-title":"Ageing Res Rev"},{"key":"2023122005152959100_bib49","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1681\/ASN.2020020151","article-title":"GFR in healthy aging: an individual participant data meta-analysis of iohexol clearance in European population-based cohorts","volume":"31","author":"Eriksen","year":"2020","journal-title":"Am Soc Nephrol"},{"key":"2023122005152959100_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2023122005152959100_bib51","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1681\/ASN.2015030337","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up","volume":"27","author":"Lenders","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2023122005152959100_bib52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/cge.14266","article-title":"New insights in efficacy of different ERT dosages in Fabry disease: switch studies data following agalsidase beta shortage","volume":"103","author":"Riccio","year":"2023","journal-title":"Clin Genet"},{"key":"2023122005152959100_bib53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"key":"2023122005152959100_bib54","first-page":"S188","article-title":"Differential effects of agalsidase alfa and agalsidase beta in Fabry outcomes: 10 year outcomes from the Canadian Fabry disease initiative","volume":"41(S1)","author":"Sirrs","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"2023122005152959100_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol Genet Metab"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad164\/51575798\/gfad164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/1\/18\/54633896\/gfad164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/1\/18\/54633896\/gfad164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:15:55Z","timestamp":1703031355000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/1\/18\/7223980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,13]]},"published-print":{"date-parts":[[2023,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad164","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,7,13]]}}}